Franklin Resources Inc. Makes New Investment in Omeros Co. (NASDAQ:OMER)

Franklin Resources Inc. purchased a new stake in shares of Omeros Co. (NASDAQ:OMER) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 13,186 shares of the biopharmaceutical company’s stock, valued at approximately $130,000.

A number of other hedge funds also recently modified their holdings of OMER. Barclays PLC raised its position in Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares during the last quarter. State Street Corp lifted its stake in shares of Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the period. HighTower Advisors LLC boosted its holdings in Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,000 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Omeros during the 4th quarter valued at approximately $46,000. Finally, MML Investors Services LLC raised its holdings in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, April 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Friday, April 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Up 0.3 %

NASDAQ:OMER opened at $6.78 on Friday. Omeros Co. has a twelve month low of $2.97 and a twelve month high of $13.60. The company has a fifty day moving average of $8.01 and a 200-day moving average of $7.85. The firm has a market capitalization of $393.67 million, a P/E ratio of -2.94 and a beta of 2.35.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter in the prior year, the company earned ($0.15) earnings per share. On average, analysts anticipate that Omeros Co. will post -3.09 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.